Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India · Delayed Price · Currency is INR 233.35
+0.36 (0.15%)
Sep 11, 2026, 3:30 PM IST
Jagsonpal Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,938 | 2,872 | 2,687 | 2,087 | 2,367 | 2,176 |
| 2,938 | 2,872 | 2,687 | 2,087 | 2,367 | 2,176 | |
Revenue Growth | 3.87% | 6.89% | 28.76% | -11.83% | 8.79% | 15.77% |
Cost of Revenue | 1,061 | 1,056 | 973.63 | 805.48 | 926.98 | 896.91 |
Gross Profit | 1,878 | 1,817 | 1,714 | 1,282 | 1,440 | 1,279 |
Selling, General & Admin | 740.77 | 915.66 | 884.99 | 635.52 | 729.76 | 703.71 |
Other Operating Expenses | 525.95 | 320.1 | 317.83 | 272.55 | 269.53 | 319.67 |
Operating Expenses | 1,359 | 1,330 | 1,284 | 1,065 | 1,101 | 1,039 |
Operating Income | 518.68 | 486.3 | 429.4 | 216.07 | 338.85 | 239.87 |
Interest Expense | -10.25 | -8.32 | -8.58 | -7.77 | -2.78 | -2.61 |
Interest & Investment Income | - | 117.43 | 76.45 | 85.92 | 34.28 | 15.46 |
Other Non Operating Income (Expenses) | 120.03 | 0.56 | 4.45 | 4.47 | 3.11 | 1.5 |
EBT Excluding Unusual Items | 628.46 | 595.97 | 501.72 | 298.69 | 373.46 | 254.22 |
Merger & Restructuring Charges | - | - | -34.97 | - | - | - |
Impairment of Goodwill | - | - | - | - | -0.3 | - |
Gain (Loss) on Sale of Investments | - | - | - | - | 5.92 | 11.35 |
Gain (Loss) on Sale of Assets | - | - | - | - | 3.59 | 0.85 |
Asset Writedown | - | - | -1.75 | - | -27.79 | - |
Other Unusual Items | -20.79 | -20.79 | 233.59 | - | -6.8 | - |
Pretax Income | 607.67 | 575.18 | 698.59 | 298.69 | 348.08 | 266.42 |
Income Tax Expense | 152.91 | 144.36 | 144.98 | 74.06 | 80.87 | 77.87 |
Net Income | 454.76 | 430.82 | 553.61 | 224.63 | 267.21 | 188.55 |
Net Income to Common | 454.76 | 430.82 | 553.61 | 224.63 | 267.21 | 188.55 |
Net Income Growth | -25.24% | -22.18% | 146.45% | -15.93% | 41.72% | 10.53% |
Shares Outstanding (Basic) | 67 | 67 | 67 | 66 | 65 | 65 |
Shares Outstanding (Diluted) | 68 | 68 | 67 | 66 | 65 | 65 |
Shares Change | 1.07% | 1.33% | 1.56% | 1.23% | - | - |
EPS (Basic) | 6.79 | 6.40 | 8.26 | 3.40 | 4.08 | 2.88 |
EPS (Diluted) | 6.70 | 6.31 | 8.22 | 3.39 | 4.08 | 2.88 |
EPS Growth | -26.03% | -23.18% | 142.48% | -16.91% | 41.72% | 10.55% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 466.64 | 547.65 | 349.18 | 463.37 | 58.65 |
Free Cash Flow Per Share | - | 6.84 | 8.13 | 5.27 | 7.08 | 0.90 |
Dividend Per Share | - | 2.500 | 2.500 | 2.000 | 2.000 | 1.600 |
Dividend Growth | - | 0% | 25.00% | 0% | 25.00% | 300.00% |
Gross Margin | 63.90% | 63.24% | 63.77% | 61.41% | 60.84% | 58.78% |
Operating Margin | 17.65% | 16.93% | 15.98% | 10.35% | 14.31% | 11.02% |
Profit Margin | 15.48% | 15.00% | 20.60% | 10.76% | 11.29% | 8.67% |
Free Cash Flow Margin | - | 16.25% | 20.38% | 16.73% | 19.57% | 2.70% |
EBITDA | 620 | 564.72 | 496.31 | 221.13 | 347.11 | 255.13 |
EBITDA Margin | 21.10% | 19.66% | 18.47% | 10.60% | 14.66% | 11.73% |
D&A For EBITDA | 101.32 | 78.42 | 66.91 | 5.06 | 8.26 | 15.26 |
EBIT | 518.68 | 486.3 | 429.4 | 216.07 | 338.85 | 239.87 |
EBIT Margin | 17.65% | 16.93% | 15.98% | 10.35% | 14.31% | 11.02% |
Effective Tax Rate | 25.16% | 25.10% | 20.75% | 24.80% | 23.23% | 29.23% |
Revenue as Reported | 3,058 | 2,992 | 2,769 | 2,180 | 2,424 | 2,210 |
Advertising Expenses | - | 207.97 | 175.42 | 138.58 | 147.3 | 102.19 |